Bacterial Cocktail Treats Infection

Mice fed a mix of six strains of bacteria were able to fight a C. difficile infection that causes deadly diarrhea and is resistant to most types of treatment.

Written byEdyta Zielinska
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

C. difficile cultures
Wikimedia, CDC, Holdeman
Clostridium difficile
is a common disease in hospitals and nursing homes and causes some 14,000 deaths each year in the United States. The disease can be treated with antibiotics, but the bacteria produce spores that resist common disinfection techniques, resulting in a high rate of re-infection. (See “Wrestling with Recurrent Infections,” The Scientist, May 2011, for an overview of C. difficile infections and treatment options.) Now, researchers from the Wellcome Trust Sanger Institute have isolated a combination of six other bacteria species that successfully fight C. difficile infections in mice, potentially paving the way toward standardized therapy, according to a report in PLOS Pathology last week (October 25).

The only successful treatment to date has been fecal therapy, which involves the transfer of fecal material from a healthy individual directly into the intestines of an infected patient. However, the treatment is controversial because it risks introducing pathogenic strains, in addition to the healthful ones. Instead, the Sanger Institute researchers took fecal matter that successfully cured mice and cultured the bacteria from it. They isolated 18 types of bacteria and determined that a mixture of six of those was sufficient to successfully treat the disease.

“Fecal transplantation is viewed as an alternative treatment, but it is not widely used because of the risk of introducing harmful pathogens as well as general patient aversion,” lead author Gordon Dougan from the Wellcome Trust Sanger Institute, in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies